サンプル依頼リスト カート
  • English
  • Korean
表紙：心膜炎の世界市場-2023年～2030年
市場調査レポート
商品コード
1373365

心膜炎の世界市場-2023年～2030年

Global Pericarditis Market - 2023-2030

出版日
ページ情報
英文 195 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
心膜炎の世界市場-2023年～2030年
出版日: 2023年10月18日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

心膜炎の概要

心膜炎は心臓の内膜である心膜の炎症によって引き起こされ、主にウイルス、ループスのような炎症性疾患、関節リウマチが原因となります。心膜炎の治療には抗炎症薬や副腎皮質ステロイドが使用されます。持続期間によって、急性心膜炎と慢性心膜炎の2種類に分けられます。心膜炎はインフルエンザ感染によって引き起こされるため、COVID患者にもみられます。

National Center for Biotechnology Informationによると、一般人口における急性心膜炎の発症率は、年間10万人あたり約27.7人です。しかし、心膜炎感染にはウイルス性、細菌性、真菌性など多くの原因があります。症状はあまり変わりません。ほとんどすべての人に胸痛、発汗、息苦しさを引き起こします。

市場力学：市場促進要因と市場抑制要因

ウイルス関連心膜炎の有病率の増加

心膜炎はウイルス感染と併発することが多いため、ウイルス感染が心膜炎の世界の主要原因となっています。ハーバード・ヘルスによれば、心膜炎の最初の誘因はウイルス感染であり、ウイルス感染によって心臓を含む様々な臓器に体液が貯留するためです。心膜炎の原因はウイルス、細菌、自己免疫疾患など多くの要因に左右されるため、予防よりも治療の方が現実的です。

世界保健機関（WHO）2022年問題によると、毎年、季節性インフルエンザに関連する呼吸器疾患だけで推定65万人が死亡しています。インフルエンザは、感染が心臓に移動し、心膜に炎症を引き起こすため、心膜炎を引き起こします。

COVID-19でも、インフルエンザが体のほぼすべての部位に広がって炎症を引き起こすため、心膜炎の症例が報告されています。2022年12月現在、6,618,579人のCOVIDによる死亡が報告されており、そのほとんどが心臓に炎症を起こしていました。例えば、AHAジャーナル2023年号によると、SARS-CoV-2は心筋炎/心膜炎の発生率をCOVID以前のレベルより少なくとも15倍増加させたが、この症状はまだまれです。

さらに、心臓疾患の有病率の増加、技術革新の進展、より良い診断と治療の進歩が、今後一定期間の市場を牽引する要因です。

心膜切除術の副作用

心膜切除術の副作用には、過剰出血、心房および心室の不整脈、さらには心室壁の破裂などがあります。血栓や感染症も心膜切除術を受けた患者の一部に認められます。このようなリスクを克服することは，手術が危険を伴うものである以上，困難です。そのため、心膜炎のほとんどの症例は抗炎症薬を用いて治療されており、治療可能な副作用も少なくなっています。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • ウイルス性心膜炎の有病率の増加
      • 抑制要因
    • 抑制要因
      • 心膜切除術の副作用
      • はい
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 地域分析
  • 規制分析
  • DMI意見

第6章 COVID-19分析

第7章 疾患タイプ別

  • 急性心膜炎
  • 急性心膜炎
  • 慢性心膜炎
  • その他

第8章 治療タイプ別

  • 薬剤
    • 鎮痛剤
    • アスピリン
    • イブプロフェン
    • 抗炎症薬
    • コルヒチン
    • コルチコステロイド
    • その他
  • 手技
    • 心嚢穿刺
    • 心膜切除術
    • その他

第9章 エンドユーザー別

  • 病院およびクリニック
  • 心臓センター
  • その他

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第12章 企業プロファイル

  • Teva Pharmaceuticals USA, Inc.
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • Par Pharmaceutical
  • Merck KGaA
  • Cumberland Pharmaceuticals Inc.
  • Johnson & Johnson Inc.
  • Bayer AG
  • Midas Pharma GmbH.
  • Alchem International Pvt. Ltd.
  • Takeda Pharmaceutical Company Limited
  • Azure Pharmaceuticals

第13章 付録

目次
Product Code: PH1784

Overview

Pericarditis is caused by inflammation of the pericardium, the lining of the heart, mainly driven by viruses, inflammatory diseases like lupus, and rheumatoid arthritis. Anti-inflammatory agents and corticosteroids are used for the treatment of pericarditis. Based on its duration, it is of two types, acute and chronic pericarditis. It is also seen in COVID patients as it is caused by flu infection.

According to the National Center for Biotechnology Information, the incidence of acute pericarditis in the general population is approximately 27.7 cases per 100,000 individuals annually. However, pericarditis infection has many causes, such as viral, bacterial, fungal, etc. The symptoms don't vary much. It causes chest pain, sweating, and breathlessness in almost every individual.

Market Dynamics: Drivers & Restraints

Increasing prevalence of virus-associated pericarditis

Viral infections are a leading cause of pericarditis worldwide, as the condition frequently coexists with viral infections. According to Harvard Health, the initial trigger for pericarditis is viral infections, as they cause fluid accumulation in various organs, including the heart. Treatment is more feasible than prevention because the cause of the disease is dependent on many factors, such as viruses, bacteria, autoimmune disorders, etc.

According to the World Health Organisation 2022 issue, every year, an estimated 650,000 deaths are caused due to respiratory diseases linked to seasonal influenza alone. Influenza leads to pericarditis as the infection moves to the heart and causes inflammation in the pericardium.

COVID-19 also reported pericarditis cases as the flu spread to almost every part of the body and caused inflammation. As of December 2022, 6,618,579 COVID deaths have been reported, most of which had heart inflammation. For instance, according to the AHA journal 2023 issue, SARS-CoV-2 increased the incidence of myocarditis/pericarditis by at least 15× over pre-COVID levels, although the condition remains rare.

Furthermore, increased prevalence of heart diseases, increased innovations, and advancements in better diagnosis and treatment are the factors that drive the market in the forthcoming period.

Side effects of pericardiectomy

Side effects of Pericardiectomy include excessive bleeding, atrial and ventricular arrhythmia, and even ventricular wall rupture. Blood clots and infection are also observed in a few patients undergoing Pericardiectomy. Overcoming these risks is difficult as the procedures are risky to perform. Hence, most pericarditis cases are treated using anti-inflammatory drugs, which causes fewer side effects that are often treatable.

Segment Analysis

The global pericarditis market is segmented based on disease type, treatment type, end user and region.

The Anti inflammatory drugs segment accounted for approximately 45.8% of the market share

Anti-inflammatory drugs are the first-line treatment for pericarditis. Companies are currently working on the same with increased efficacy and safety. The United States Food and Drug Administration is supporting Cardiol Therapeutics Inc. in conducting two Phase II studies in rare heart diseases, recurrent pericarditis, and acute myocarditis, as no other drugs are currently discovered for rare heart diseases like pericarditis.

In November 2022, Cardiol Therapeutics Inc. declared positive results demonstrating the protective effects of CardiolRx. It significantly reduces pericardial effusion and thickening of the pericardium.

In January 2023, Cardiol Therapeutics Inc. declared that the first patient had been enrolled in the company-sponsored Phase II study evaluating the tolerance, safety, and efficacy of CardiolRx in patients with recurrent pericarditis.

Geographical Analysis

North America accounted for approximately 40.6% of the market share in 2022

North America is expected to hold the largest market share due to the incidence of pericarditis in patients who received vaccines developed by U.S. companies. Pericarditis causes heart failure that affects more than 64 million people globally, and associated healthcare costs exceed $30 billion annually in the U.S. alone. The disease is diagnosed in 0.2% of all cardiovascular in-hospital admissions and is responsible for 5% of emergency room admissions for chest pain in North America and Western Europe.

More than 22 million doses of Moderna have been administered in Canada, where the incidence of myocarditis, pericarditis, or myopericarditis is two to threefold higher after a second dose of the Moderna Spikevax COVID-19 vaccine than the Pfizer vaccine. Forty-one pericarditis cases were immediately observed after the Moderna vaccine in Canada.

COVID-19 Impact Analysis:

COVID-19 had a slight, moderate impact on the pericarditis market. The supply chains were interrupted during the peak period of the infection. Most of the diagnostic centers were shut down due to the implementation of lockdowns worldwide. This impacted the diagnosis and, thus, treatment procedures for cardiovascular diseases, including pericarditis.

Many of them were postponed and diagnosed at later stages as there are many types of pericarditis with different causes; the treatment options vary, with individuals requiring extensive testing that was shut down entirely during the 19 period. Hence, all the research focused on vaccines and covid drug development.

Competitive Landscape

The major global players in the pericarditis market include: Teva Pharmaceuticals USA, Inc., Par Pharmaceutical, Merck KGaA, Cumberland Pharmaceuticals Inc., Johnson & Johnson Inc., Bayer AG, Midas Pharma GmbH., Alchem International Pvt. Ltd., Takeda Pharmaceutical Company Limited, Azure Pharmaceuticals among others.

Key Developments

  • Rabin Medical Center is conducting phase 4 clinical trials to compare the efficacy of NSAID therapy and Dexamethasone therapy in patients suffering from pericarditis. The study start date is February 14, 2020. The estimated completion date is December 2023.
  • In March 2021, Kiniksa Pharmaceuticals, Ltd. Received the U.S. Food and Drug Administration (FDA) approval for ARCALYST for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children 12 years and older. It was commercially launched in August 2021.

Why Purchase the Report?

  • To visualize the global pericarditis market segmentation based on disease type, treatment type, end user and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of pericarditis market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global pericarditis market report would provide approximately 63 tables, 65 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Disease Type
  • 3.2. Snippet by Treatment Type
  • 3.3. Snippet by End User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Driver
      • 4.1.1.1. Increasing prevalence of virus-associated pericarditis
      • 4.1.1.2.
    • 4.1.2. Restraints
      • 4.1.2.1. Side effects of pericardiectomy
      • 4.1.2.2.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regional Analysis
  • 5.5. Regulatory Analysis
  • 5.6. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Disease Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 7.1.2. Market Attractiveness Index, By Disease Type
  • 7.2. Acute Pericarditis*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Incessant Pericarditis
  • 7.4. Chronic Pericarditis
  • 7.5. Others

8. By Treatment Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.1.2. Market Attractiveness Index, By Treatment Type
  • 8.2. Drug*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
      • 8.2.2.1. Pain Relievers
      • 8.2.2.1.1.1. Aspirin
      • 8.2.2.1.1.2. Ibuprofen
      • 8.2.2.2. Anti-inflammatory drugs
      • 8.2.2.2.1.1. Colchicine
      • 8.2.2.2.1.2. Corticosteroids
      • 8.2.2.2.1.3. Others
  • 8.3. Procedure
      • 8.3.1.1. Pericardiocentesis
      • 8.3.1.2. Pericardiectomy
      • 8.3.1.3. Others

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User
  • 9.2. Hospitals and Clinics*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Cardiac Centers
  • 9.4. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Teva Pharmaceuticals USA, Inc.
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Par Pharmaceutical
  • 12.3. Merck KGaA
  • 12.4. Cumberland Pharmaceuticals Inc.
  • 12.5. Johnson & Johnson Inc.
  • 12.6. Bayer AG
  • 12.7. Midas Pharma GmbH.
  • 12.8. Alchem International Pvt. Ltd.
  • 12.9. Takeda Pharmaceutical Company Limited
  • 12.10. Azure Pharmaceuticals

LIST NOT EXHAUSTIVE.

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us